Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001178913-26-002068
Filing Date
2026-04-10
Accepted
2026-04-10 16:12:30
Documents
1
Period of Report
2026-03-18

Document Format Files

Seq Description Document Type Size
1 FORM 3 zk2635030.html 3  
1 FORM 3 zk2635030.xml 3 11402
  Complete submission text file 0001178913-26-002068.txt   13112
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV Israel
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV Israel 972-77-331-0156
Chemomab Therapeutics Ltd. (Issuer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | State of Incorp.: L3 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O INNOVATE BIOPHARMACEUTICALS, INC. 8480 HONEYCUTT ROAD, SUITE 120 RALEIGH NC 27615
Business Address
Darvish Nissim (Reporting) CIK: 0001793602 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38807 | Film No.: 26854997